

## **Biosimilars (2009 - 2014)**

<https://marketpublishers.com/r/BB546E643E6EN.html>

Date: September 2009

Pages: 189

Price: US\$ 5,650.00 (Single User License)

ID: BB546E643E6EN

### **Abstracts**

The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US\$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others.

The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics worth US\$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market.

Asia's early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly fragmented with major players such as Biocon, Dr. Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. Favorable regulatory developments in the biosimilars sector are expected to increase the market shares and profit margins while reducing medical expenditure.

### **Scope of the Report**

This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

- **Biosimilars product market**

Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others

- **Biosimilars service market**

Contract research and manufacturing services, clinical trials services

- **Biosimilars applications market**

Oncology, infectious diseases, chronic and autoimmune diseases, and other diseases

- **Biosimilars technology market**

Recombinant DNA technology, monoclonal antibodies technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

### **What makes our reports unique?**

- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
- Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and a minimum of 50 micro markets, which are collectively exhaustive and mutually exclusive.
- No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies - US, Europe, APAC, ROW (Rest of the World).
- We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.

- 15 pages of high level analysis including benchmarking strategies, best practices and the market's cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
- Comprehensive market analysis for the following sectors: Pharmaceuticals, medical devices, biotechnology, semiconductor and electronics, energy and power supplies, food and beverages, chemicals, advanced materials, industrial automation, and telecom and it. we also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

#### Key questions answered

- Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

#### Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

## Contents

### 1. INTRODUCTION

- 1.1. KEY TAKE AWAYS
- 1.2. REPORT DESCRIPTION
- 1.3. SCOPE OF THE REPORT
- 1.4. STAKEHOLDERS

### 2. SUMMARY

- 2.1. GLOSSARY

### 3. MARKET OVERVIEW

- 3.1. ISSUES RELATED WITH BIOSIMILAR
- 3.2. DEFINING THE GLOBAL BIOSIMILAR MARKET
- 3.3. DRIVING FACTOR ANALYSIS
  - 3.3.1. DEMAND-SIDE DRIVERS
  - 3.3.2. SUPPLY-SIDE DRIVERS
  - 3.3.3. RESTRAINTS & OPPORTUNITIES
  - 3.3.4. KEY COMPETITIVE POINTS
- 3.4. POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR PRODUCTS
- 3.5. POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR APPLICATIONS
- 3.6. BIOSIMILAR MARKET DYNAMICS
- 3.7. COMPARISON OF BIOSIMILAR AND GENERIC DRUGS
- 3.8. PRICING OF BIOSIMILAR DRUG
- 3.9. SUPPLY SIDE STAKEHOLDERS
  - 3.9.1. Innovator drug manufacturers
  - 3.9.2. drug device manufacturers & next-generation innovators
- 3.10. BIOSIMILAR PRODUCTS GEOGRAPHICAL TRENDS
- 3.11. CYCLE OF INNOVATION AND COMPETITION

### 4. BIOSIMILAR PRODUCTS

#### SUMMARY

- 4.1. RECOMBINANT NON-GLYCOSYLATED PROTEIN
  - 4.1.1. DRIVERS

#### 4.1.2. INSULIN

##### 4.1.2.1. Drivers & Opportunities

4.1.2.1.1. Increasing demand from huge patient-base

4.1.2.1.2. Improvements in drug delivery method

#### 4.1.3. RECOMBINANT HUMAN GROWTH HORMONE

#### 4.1.4. LEPIRUDIN

#### 4.1.5. INTERLEUKIN – 2 (IL-2)

#### 4.1.6. INTERFERONS

4.1.6.1. Interferon Alfa

4.1.6.2. Interferon beta-1a

4.1.6.3. Interferon gamma

#### 4.1.7. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF)

#### 4.1.8. INTERLEUKIN-11

#### 4.1.9. ANAKINRA

### 4.2. RECOMBINANT GLYCOSYLATED PROTEINS

#### 4.2.1. DRIVERS & RESTRAINTS

4.2.1.1. Applications in many therapeutic indications

4.2.1.2. Segment covers major drug categories

4.2.1.3. Requires high degree of clinical and manufacturing expertise

#### 4.2.2. ERYTHROPOIETIN (EPO)

#### 4.2.3. FOLLITROPIN

#### 4.2.4. HYROTROPIN

#### 4.2.5. UROKINASE

#### 4.2.6. GLUCOCEREBROSIDASE

#### 4.2.7. BECAPLERMIN

#### 4.2.8. GRANULOCYTE-MACROPHAGE-CSF (GM-CSF)

#### 4.2.9 RECOMBINANT HUMAN DNASE (RHDNASE)

#### 4.2.10.FACTOR VIIA

#### 4.2.11.FACTOR VIII

#### 4.2.12.FACTOR IX

#### 4.2.13.ACTIVATED PROTEIN C

#### 4.2.14.TISSUE PLASMINOGEN ACTIVATOR

#### 4.2.15.MONOCLONAL ANTIBODIES

4.2.15.1. Chimaeric Antibodies

4.2.15.2. Humanized / CDR-grafted / Reshaped antibodies

4.2.15.3. Human antibodies and fusion protein

### 4.3. PEPTIDES

#### 4.3.1. DRIVERS

- 4.3.1.1. Development of synthetic and biological peptide libraries
- 4.3.1.2. Fewer side effects and maximum therapeutic index

#### 4.3.2. RESTRAINTS & OPPORTUNITIES

- 4.3.2.1. Short half-life of peptide molecules
- 4.3.2.2. Costly manufacturing and purification process
- 4.3.2.3. Approval of drug candidates in Phase II & III

#### 4.3.3. OCTREOTIDE

#### 4.3.4. DESMOPRESSIN

#### 4.3.5. CYCLOSPORINE

#### 4.3.6. CALCITONIN

#### 4.3.7. EPTIFIBATIDE

#### 4.3.8. LH-RH (LEUPROLIDE)

#### 4.3.9. NESIRITIDE

#### 4.3.10. TERIPARATIDE

#### 4.3.11. BIVALIRUDIN

#### 4.3.12. ENFUVIRTIDE

#### 4.3.13. GLUCAGON

## 5. BIOSIMILAR SERVICE MARKET

### SUMMARY

#### 5.1. CONTRACT RESEARCH AND MANUFACTURING SERVICES

##### 5.1.1. DRIVERS

- 5.1.1.1. Outsourcing non-core activities to low cost destinations
- 5.1.1.2. Time consuming nature of drug manufacturing

##### 5.1.2. RESTRAINTS & OPPORTUNITIES

- 5.1.2.1. Long inception period
- 5.1.2.2. Low returns
- 5.1.2.3. Emergence of biosimilars

#### 5.2. CLINICAL TRIALS

##### 5.2.1. DRIVERS & RESTRAINTS

- 5.2.1.1. Extensive information about new drug candidate
- 5.2.1.2. Central role in drug development

##### 5.2.2. High cost

##### 5.2.3 PHASE I

##### 5.2.4. PHASE II

##### 5.2.5. PHASE III

## **6. BIOSIMILAR APPLICATION MARKET**

### **SUMMARY**

#### **6.1. DRIVERS**

- 6.1.1. Prevalence of incurable diseases
- 6.1.2. Expanding patient population
- 6.1.3. Developed technology
- 6.1.4. Increased life expectancy

#### **6.2. RESTRAINTS**

- 6.2.1. Failure of clinical research
- 6.2.2. Adverse effects of therapies

#### **6.3. ONCOLOGY**

##### **6.3.1. DRIVERS**

- 6.3.1.1. Unraveling of the genetics behind cancer
- 6.3.1.2. Significance and variants
- 6.3.1.3. Availability of new treatments
- 6.3.1.4. Increase in the ageing population

##### **6.3.2. RESTRAINTS & OPPORTUNITIES**

- 6.3.2.1. Lack of early stage diagnostic
- 6.3.2.2. Unawareness and lack of penetration of therapeutics
- 6.3.2.3. Large product pipeline

##### **6.3.3. LUNG CANCER**

##### **6.3.4. COLORECTAL CANCER**

##### **6.3.5. BREAST CANCER**

##### **6.3.6. CERVICAL CANCER**

##### **6.3.7. LEUKEMIA**

###### **6.3.7.1. Drivers**

- 6.3.7.1.1. Huge market potential
- 6.3.7.1.2. Rising awareness

###### **6.3.7.2. PROSTATE CANCER**

#### **6.4. INFECTIOUS DISEASES**

##### **6.4.1. HIV/AIDS**

###### **6.4.1.1. Drivers**

- 6.4.1.1.1. Continual research to increase market size
- 6.4.1.1.2. Biological drugs increase life expectancy
- 6.4.1.1.3. Less expensive than biological drugs

6.4.1.1.4. Lack of awareness and access among low income population

6.4.2. HEPATITIS B

6.4.3. EPATITIS C

6.5. CHRONIC AND AUTOIMMUNE DISEASES

6.5.1. DIABETES

6.5.1.1. Drivers

6.5.1.1.1. Awareness & early diagnosis prevents disease development

6.5.1.1.2. Changing approach of patients towards medication

6.5.2. NEUTROPENIA

6.5.3. MULTIPLE SCLEROSIS

6.5.3.1. Drivers

6.5.3.1.1. Rising awareness

6.5.3.1.2. Increases the life expectancy

6.5.3.1.3. Inhibitors and opportunities

6.5.4. CYSTIC FIBROSIS

6.5.5. RHEUMATOID ARTHRITIS (RA)

6.5.5.1. Drivers

6.5.5.1.1. Large patient population

6.5.5.1.2. Need for continued treatment

6.5.5.2. Restraints

6.5.6. ACROMEGALY

6.5.6.1. Driver

6.5.6.1.1. Risk of getting other diseases

6.5.6.1.2. Worldwide prevalence of the disease

6.5.7. LEPROSY

6.6. HEMATOLOGY

6.6.1. DRIVERS

6.6.1.1. Prevalence of blood-related disorders

6.6.1.2. Availability of cheaper treatment alternatives

6.6.1.3. Early start of medication and longer treatment time

6.6.2. CHEMOTHERAPY INDUCED ANEMIA

6.6.2.1. Drivers

6.6.2.1.1. Chemotherapy has become the preferred treatment

6.6.2.1.2. Availability of new treatment alternatives

6.6.2.1.3. Early and easy diagnostics drives the market

6.6.2.2. Restraints and Opportunities

6.6.3. HEMOPHILIA



#### 6.5.4. PULMONARY EMBOLISM

##### 6.6.4.1. Drivers

- 6.6.4.1.1. Availability of large number of diagnosis tools
- 6.6.4.1.2. Need for immediate medication

#### 6.7. GROWTH HORMONE DEFICIENCY (GHD)

##### 6.7.1. DRIVERS

- 6.7.1.1. Natural deficiency of GH and destruction of normal pituitary gland
- 6.7.1.2. Need for body mass management
- 6.7.1.3. Changes in the body composition

#### 6.8. OTHER DISEASES

##### 6.8.1. GAUCHER DISEASE

##### 6.8.2. OSTEOPOROSIS

##### 6.8.3. FERTILITY DISORDERS (INFERTILITY)

##### 6.8.4. SKIN ULCER

##### 6.8.5. HYPOGLYCEMIA

##### 6.8.6. NOCTURNAL ENURESIS

##### 6.8.7. CONGESTIVE HEART FAILURE (CHF)

##### 6.8.8. SYSTEMIC SEPSIS

##### 6.8.9. OTHERS

### 7. BIOSIMILAR TECHNOLOGY

#### SUMMARY

##### 7.1. MONOCLONAL ANTIBODIES (MAB) TECHNOLOGY

###### 7.1.1. DRIVERS

- 7.1.1.1. Broad range of therapeutic, diagnostic, and research applications
- 7.1.1.2. Low cost of development
- 7.1.1.3. Higher success rate

###### 7.1.2. TOP PLAYER ANALYSIS

##### 7.2. RECOMBINANT DNA TECHNOLOGY (RDNA TECHNOLOGY)

###### 7.2.1. DRIVERS

- 7.2.1.1. Human therapeutics application
- 7.2.1.2. Agricultural genetic engineering application
- 7.2.1.3. Increase in demand of biopharmaceutical products

###### 7.2.2. RESTRAINTS & OPPORTUNITIES

- 7.2.2.1. High Cost

7.2.2.2. Risk of failure

7.2.2.3. Role in production of edible vaccines

### 7.3. CHROMATOGRAPHY

#### 7.3.1. DRIVERS & OPPORTUNITIES

7.3.1.1. High resolution refinement

7.3.1.2. Efficacy of end product

7.3.1.3. Wide applications

7.3.1.4. Emergence of biosimilars

#### 7.3.2. TOP PLAYER ANALYSIS

#### 7.3.3. LIQUID CHROMATOGRAPHY (LC)

#### 7.3.4. GAS CHROMATOGRAPHY (GC)

### 7.4. PROTEIN SEQUENCING

#### 7.4.1. DRIVERS

7.4.1.1. Applications in life saving drug development

7.4.1.2. Applications in protein classification

7.4.1.3. Use in diagnosis

### 7.5. NUCLEAR MAGNETIC RESONANCE (NMR) TECHNOLOGY

#### 7.5.1. DRIVERS

7.5.1.1. Leading technology for 3-D structure

7.5.1.2. Eliminates risk of x-radiation

7.5.1.3. Application in drug delivery system

### 7.6. ELECTROPHORESIS

#### 7.6.1. DRIVERS

7.6.1.1. Genomic application

7.6.1.2. Most reliable technique

7.6.1.3. Separation Efficacy

#### 7.6.2. RESTRAINTS & OPPORTUNITIES

7.6.2.1. High sample runtime

#### 7.6.3. GEL ELECTROPHORESIS

#### 7.6.4. CAPILLARY ELECTROPHORESIS

### 7.7. MASS SPECTROMETRY

#### 7.7.1. DRIVERS

7.7.1.1. Simple Quantification of Protein Structures

7.7.1.2. Supporting Element for Growing Technologies:

7.7.1.3. Gaining Popularity of Hybrid Mass Spectrometry Instruments

#### 7.7.2. RESTRAINTS

7.7.2.1. Fails to Analyze Small Quantities of Proteins

7.7.2.2. Manual Interruption Necessary, Increasing the Error Rate

### 7.8. WESTERN BLOTTING

#### 7.8.1. DRIVERS

7.8.1.1. Application in molecular biology disciplines

7.8.1.2. Application in diagnosis of diseases

7.8.1.3. High efficacy at low cost

### 7.9. BIOASSAY

#### 7.9.1. DRIVERS

7.9.1.1. Central role in new drug development

7.9.1.2. Monitoring environmental pollutants

7.9.1.3. Cost benefits and error reduction

7.9.1.4. Shrinking pipelines of new drug candidates

7.9.1.5. Increasing price pressures in the U.S. and Europe

#### 7.9.2. RESTRAINTS

7.9.2.1. Accuracy of experiment not guaranteed

7.9.2.2. Time-consuming, laborious, and organism-specific activity

#### 7.9.3. TECHNIQUES IN BIOASSAY

7.9.3.1. Six Point Assay

7.9.3.2. Multiple Point Assays

7.9.3.3. Interpolation Method

7.9.3.4. Bracketing Method

7.9.3.5. Matching Bioassays

## 8. GEOGRAPHIC ANALYSIS

### 8.1. AMERICAN BIOSIMILAR MARKET

8.1.1. Large patient base and high Medicare expenditure

8.1.2. Largest Biopharmaceutical market

### 8.2. EUROPEAN BIOSIMILAR MARKET

### 8.3. ASIAN BIOSIMILAR MARKET

### 8.4. ROW BIOSIMILAR MARKET

## 9. REGULATORY GUIDELINES

- 9.1. AMERICA
  - 9.1.1. CANADA
  - 9.1.2. U.S.

- 9.2. ASIA
  - 9.2.1. JAPAN
  - 9.2.2. HINA
  - 9.2.3. NDIA
  - 9.2.4. UROPE
  - 9.2.5. ROW

## **10.COMPANY PROFILES**

- 10.1. 3SBIO (SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD)
- 10.2. ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD
- 10.3. BHARAT BIOTECH
- 10.4. BIOCLONES (PTY) LTD.
- 10.5. BIOCON
- 10.6. BIOGNERIX AG
- 10.7. BIOPARTNERS
- 10.8. CANGENE
- 10.9. CINNAGEN INC.
- 10.10. CLARIS LIFESCIENCES
- 10.11. DONG-A PHARMACEUTICAL
- 10.12. DR. REDDY'S LABORATORIES
- 10.13. DSM BIOLOGICS
- 10.14. DYNAVAX TECHNOLOGIES
- 10.15. EMCURE
- 10.16. GENESCIENCE PHARMACEUTICALS CO LTD.
- 10.17. GLENMARK PHARMACEUTICALS
- 10.18. GTC BIOTHERAPEUTICS LTD.
- 10.19. HOSPIRA INC.
- 10.20. INTAS BIOPHARMACEUTICALS LTD.
- 10.21. LG LIFE SCIENCES
- 10.22. MAXYGEN
- 10.23. MERCK
- 10.24. MOMENTA
- 10.25. PANACEA BIOTECH
- 10.26. PHAGE BIOTECH CORPORATION
- 10.27. PHARMACLON

- 10.28. PROLONG PHARMACEUTICALS
- 10.29. RANBAXY
- 10.30. RELIANCE GENEMEDIX PLC 1
- 10.31. SANDOZ (NOVARTIS PHARMACEUTICAL)
- 10.32. SCIGEN
- 10.33. SCINOPHARM TAIWAN, LTD.
- 10.34. SHANTHA BIOTECH
- 10.35. SHENZHEN NEPTUNUS INTERLONG
- 10.36. SHREYA LIFE SCIENCES LTD.
- 10.37. STADA ARZNEIMITTEL AG
- 10.38. TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 10.39. VIOPRO INTERNATIONAL INC.
- 10.40. WOCKHARDT LIMITED

## **11.PATENT ANALYSIS**

- 11.1. PATENT EXPIRATION IN 2008 AND BEFORE
- 11.2. PATENT EXPIRATION IN 2009 AND AFTER

## **APPENDIX**

PATENT EXPIRY IN 2008 AND BEFORE

U.S. BIOPHARMACEUTICAL PATENTS

EUROPEAN BIOPHARMACEUTICAL PATENTS

ASIAN BIOPHARMACEUTICAL PATENTS

PATENT EXPIRY IN 2009 AND AFTER

U.S. BIOPHARMACEUTICAL PATENTS

EUROPEAN BIOPHARMACEUTICAL PATENTS

ASIAN BIOPHARMACEUTICAL PATENTS

## List Of Tables

### LIST OF TABLES

SUMMARY TABLE GLOBAL BIOSIMILAR MARKET, BY PRODUCTS 2007 – 2014(\$ THOUSANDS)

TABLE 1 GLOBAL BIOSIMILAR NON-GLYCOSYLATED PROTEIN MARKET, BY PRODUCT 2007 – 2014 (\$ THOUSANDS)

TABLE 2 GLOBAL BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEIN MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 3 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS

TABLE 4 GLOBAL BIOSIMILAR RECOMBINANT INSULIN MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 5 GLOBAL BIOSIMILAR RHGH MARKET, BY GEOGRAPHY 2007 – 2014(\$ THOUSANDS)

TABLE 6 GLOBAL BIOSIMILAR LEPIRUDIN MARKET, BY GEOGRAPHY 2007 – 2014(\$ THOUSANDS)

TABLE 7 GLOBAL BIOSIMILAR RECOMBINANT INTERLEUKIN–2 MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 8 GLOBAL BIOSIMILAR RECOMBINANT INTERFERONS MARKET, BY PRODUCT 2007 – 2014 (\$ THOUSANDS)

TABLE 9 GLOBAL BIOSIMILAR RECOMBINANT INTERFERONS MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 10 GLOBAL BIOSIMILAR RECOMBINANT INTERFERON ALFA MARKET BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 11 GLOBAL BIOSIMILAR RECOMBINANT INTERFERON BETA–1A MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 12 GLOBAL BIOSIMILAR RECOMBINANT INTERFERON GAMMA MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 13 GLOBAL BIOSIMILAR RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 14 GLOBAL BIOSIMILAR RECOMBINANT INTERLEUKIN–11 MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 15 GLOBAL BIOSIMILAR RECOMBINANT ANAKINRA MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 16 GLOBAL BIOSIMILAR GLYCOSYLATED PROTEIN MARKET, BY PRODUCTS 2007 – 2014 (\$ THOUSANDS)

TABLE 17 GLOBAL BIOSIMILAR GLYCOSYLATED PROTEIN MARKET, BY

GEOGRAPHY2007 – 2014 (\$ THOUSANDS)

TABLE 18 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS 56

TABLE 19 GLOBAL BIOSIMILAR RECOMBINANT EPO MARKET, BY  
GEOGRAPHY2007 – 2014 (\$ THOUSANDS)

TABLE 20 GLOBAL BIOSIMILAR FOLLITROPIN MARKET, BY GEOGRAPHY2007 –  
2014 (\$ THOUSANDS)

TABLE 21 GLOBAL BIOSIMILAR THYROTROPIN MARKET, BY GEOGRAPHY 2007 –  
2014 (\$ THOUSANDS)

TABLE 22 GLOBAL BIOSIMILAR UROKINASE MARKET, BY GEOGRAPHY 2007 –  
2014(\$ THOUSANDS) 61

TABLE 23 GLOBAL BIOSIMILAR GLUCOCEREBROSIDASE MARKET, BY  
GEOGRAPHY2007 – 2014 (\$ THOUSANDS)

TABLE 24 GLOBAL BIOSIMILAR BECAPLERMIN MARKET, BY GEOGRAPHY 2007 –  
2014 (\$ THOUSANDS)

TABLE 25 GLOBAL BIOSIMILAR RECOMBINANT GM-CSF MARKET, BY  
GEOGRAPHY2007 – 2014 (\$ THOUSANDS)

TABLE 26 GLOBAL BIOSIMILAR RHDNASE MARKET, BY GEOGRAPHY 2007 –  
2014(\$ THOUSANDS)

TABLE 27 GLOBAL BIOSIMILAR FACTOR VIIA MARKET, BY GEOGRAPHY 2007 –  
2014(\$ THOUSANDS)

TABLE 28 GLOBAL BIOSIMILAR FACTOR VIII MARKET, BY GEOGRAPHY 2007 –  
2014(\$ THOUSANDS)

TABLE 29 GLOBAL BIOSIMILAR FACTOR IX MARKET, BY GEOGRAPHY 2007 –  
2014(\$ THOUSANDS)

TABLE 30 GLOBAL BIOSIMILAR ACTIVATED PROTEIN C MARKET, BY  
GEOGRAPHY2007 – 2014 (\$ THOUSANDS)

TABLE 31 GLOBAL BIOSIMILAR TPA MARKET, BY GEOGRAPHY 2007 – 2014(\$  
THOUSANDS)

TABLE 32 GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY  
GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 33 GLOBAL BIOSIMILAR PEPTIDE MARKET, BY PRODUCTS 2007 – 2014(\$  
THOUSANDS)

TABLE 34 GLOBAL BIOSIMILAR PEPTIDE MARKET, BY GEOGRAPHY 2007 –  
2014(\$ THOUSANDS)

TABLE 35 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS 75

TABLE 36 GLOBAL BIOSIMILAR OCTREOTIDE PEPTIDE MARKET, BY  
GEOGRAPHY2007 – 2014 (\$ THOUSANDS)

TABLE 37 GLOBAL BIOSIMILAR DESMOPRESSIN PEPTIDE MARKET, BY  
GEOGRAPHY2007 – 2014 (\$ THOUSANDS)

TABLE 38 GLOBAL BIOSIMILAR CYCLOSPORINE PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 39 GLOBAL BIOSIMILAR CALCITONIN PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 40 GLOBAL BIOSIMILAR EPTIFIBATIDE PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 41 GLOBAL BIOSIMILAR LH-RH PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 42 GLOBAL BIOSIMILAR NESIRITIDE PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 43 GLOBAL BIOSIMILAR TERIPARATIDE PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 44 GLOBAL BIOSIMILAR BIVALIRUDIN PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 45 GLOBAL BIOSIMILAR ENFUVIRTIDE PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 46 GLOBAL BIOSIMILAR GLUCAGON PEPTIDE MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 47 MAJOR PLAYERS AND DEVELOPMENTS

TABLE 48 GLOBAL BIOSIMILAR MARKET, BY APPLICATIONS 2007 – 2014 (\$ THOUSANDS)

TABLE 49 GLOBAL BIOSIMILAR ONCOLOGY MARKET, BY TYPES 2007 – 2014 (\$ THOUSANDS)

TABLE 50 GLOBAL BIOSIMILAR INFECTIOUS DISEASES MARKET, BY TYPES 2007 – 2014 (\$ THOUSANDS)

TABLE 51 GLOBAL BIOSIMILAR CHRONIC AND AUTOIMMUNE DISEASE MARKET, BY TYPES 2007 – 2014 (\$ THOUSANDS)

TABLE 52 GLOBAL BIOSIMILAR HEMATOLOGY MARKET, BY TYPES 2007 – 2014 (\$ THOUSANDS)

TABLE 53 GLOBAL BIOSIMILAR OTHER DISEASES MARKET, BY TYPES 2007 – 2014 (\$ THOUSANDS)

TABLE 54 MAJOR PLAYERS AND DEVELOPMENTS

TABLE 55 MAJOR PLAYERS AND DEVELOPMENTS

TABLE 56 GLOBAL BIOSIMILAR MARKET, BY GEOGRAPHY 2007 – 2014 (\$ THOUSANDS)

TABLE 57 AMERICAN BIOSIMILAR MARKET, BY SEGMENTS 2007 – 2014 (\$ THOUSANDS)

TABLE 58 EUROPEAN BIOSIMILAR MARKET, BY SEGMENTS 2007 – 2014 (\$ THOUSANDS)



TABLE 59 ASIAN BIOSIMILAR MARKET, BY SEGMENTS 2007 – 2014 (\$ THOUSANDS)

TABLE 60 ROW BIOSIMILAR MARKET, BY SEGMENTS 2007 – 2014 (\$ THOUSANDS)

## List Of Figures

### LIST OF FIGURES

FIGURE 1 MARKET TRANSITION IMPACTING BIOSIMILAR MARKET

FIGURE 2 ISSUES RELATED WITH BIOSIMILAR

FIGURE 3 BIOSIMILAR MARKET DEFINITION

FIGURE 4 DRIVING FACTOR ANALYSIS OF GLOBAL BIOSIMILAR MARKET

FIGURE 5 MARKET POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR PRODUCT MARKET, 2009

FIGURE 6 MARKET POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR APPLICATION MARKET, 2009

FIGURE 7 GLOBAL BIOSIMILAR MARKET DYNAMICS

FIGURE 8 COMPARISON OF BIOSIMILAR AND GENERIC DRUGS

FIGURE 9 PRICING OF BIOSIMILAR DRUG

FIGURE 10 SUPPLY SIDE STAKEHOLDERS

FIGURE 11 BIOSIMILAR PRODUCTS GEOGRAPHICAL TREND

FIGURE 12 CYCLE OF INNOVATION AND COMPETITION

FIGURE 13 BIOSIMILAR PRODUCT MARKET TREND

FIGURE 14 EUROPEAN BIOSIMILAR MARKET DYNAMICS

FIGURE 15 GLOBAL BIOPHARMACEUTICAL PATENTS, BY SEGMENT

FIGURE 16 GLOBAL BIOPHARMACEUTICAL PATENTS, BY GEOGRAPHY

FIGURE 17 U.S. BIOPHARMACEUTICAL PATENTS, BY SEGMENT

FIGURE 18 EUROPE BIOPHARMACEUTICAL PATENTS, BY SEGMENT

FIGURE 19 ASIA BIOPHARMACEUTICAL PATENTS, BY SEGMENT

FIGURE 20 GLOBAL BIOPHARMACEUTICAL PATENTS, BY SEGMENT

FIGURE 21 GLOBAL BIOPHARMACEUTICAL PATENTS, BY GEOGRAPHY

FIGURE 22 U.S. BIOPHARMACEUTICAL PATENTS, BY SEGMENT

FIGURE 23 EUROPE BIOPHARMACEUTICAL PATENTS, BY SEGMENT

FIGURE 24 ASIA BIOPHARMACEUTICAL PATENTS, BY SEGMENT

### LIST OF ACRONYMS AND ABBREVIATIONS

ADR – Adverse Drug Reactions

AIDS – Acquired Immunodeficiency Syndrome

ALL – Acute Lymphoblastic Leukemia

AML – Acute Myelogenous Leukemia

ANDA – Abbreviated New Drug Applications

API – Active Pharmaceutical Ingredients

CAGR – Compound Annual Growth Rate  
CBC – Complete Blood Count  
CF – Cystic Fibrosis  
CHF – Congestive Heart Failure  
CHMP – Committee for Medicinal Products for Human Use  
CLL – Chronic Lymphocytic Leukemia  
CML – Chronic Myelogenous Leukemia  
CRAMS – Contract Research And Manufacturing Services  
CZE – Capillary Zone Electrophoresis  
DI – Diabetes Insipidus  
DNA – Deoxyribo Nucleic Acid  
EBA – Expanded Bed Absorption  
ELISPOT – Enzyme-linked Immunosorbent Spot  
EMA – European Medicines Evaluation Agency  
ENF – Enfuvirtide  
EPO – Erythropoietin  
ERT – Estrogen Replacement Therapy  
EU – European Union  
FDA – Food and Drugs Administration  
GC – Gas Chromatography  
GH – Growth Hormone  
GHD – Growth Hormone Deficiency  
GP – Glycoprotein  
HAMA – Human Anti-Mouse Antibody  
HCV – Hepatitis C Virus  
HD – Hansen’s Disease  
hGH – Human Growth Hormone  
HIT – Heparin Induced Thrombocytopenia  
HIV – Human Immunodeficiency Virus  
HPV – Human Papillomavirus  
IF – Interferon  
IL – Interleukin  
IND – Investigational New Drug  
IUGR – Intrauterine Growth Retardation  
KBA – Kansas Bioscience Authority  
LC – Liquid Chromatography  
LHRH – Luteinizing and Releasing Hormone  
LMWH – Low Molecular weight Heparin  
MAB – Monoclonal Antibodies

MMF – Mycophenolate Mofetil  
MS – Multiple Sclerosis  
NDS – New Drug Submission  
NE – Nocturnal Enuresis  
NHL – Non-Hodgkin's lymphoma  
NMR – Nuclear Magnetic Resonance  
NTG – Nitroglycerine  
PCI – Percutaneous Coronary Intervention  
PE – Pulmonary Embolism  
PTCA – Percutaneous Transluminal Coronary Angioplasty  
R&D – Research and Development  
RA – Rheumatoid Arthritis  
RCC – Renal Cell Carcinoma  
RFLP – Restriction Fragment Length Polymorphism  
RHDNASE – Recombinant Human DNase  
RMS – Relapsing Multiple Sclerosis  
SBIR – Small Business Innovation Research  
SEB – Subsequent Entry Biologics  
SLE – Systemic Lupus Erythematosus  
THST – Thyroid Hormone Suppression Therapy  
tPA – Tissue Plasminogen Activator  
TSQ – Triple Stage Quad  
WHO – World Health Organization

## I would like to order

Product name: Biosimilars (2009 - 2014)

Product link: <https://marketpublishers.com/r/BB546E643E6EN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BB546E643E6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970